HECTD2 and hepatocellular carcinoma: Using both in vitro and in vivo models, we observed a significant upregulation of HECTD2 expression in lenvatinib‐resistant HCC cell lines, patient‐derived organoids, PDX mouse models, and patient cancer tissues.